Related Experiment Video
Updated: Feb 20, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Germline mutations in pancreatic cancer and potential new therapeutic options
Rille Pihlak1,2, Juan W Valle1,2, Mairéad G McNamara1,2
1Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, United Kingdom.
Abstract:
Due to short-lived treatment responses in unresectable disease, pancreatic ductal adenocarcinoma (PDAC) continues to be one of the deadliest cancers. There is availability of new information about germline and sporadic mutations in the deoxyribonucleic acid (DNA) damage repair pathway in PDAC in recent decades and the expectation is that novel targeted therapies will thus be developed. A variety of germline mutations (BRCA2, BRCA1, PALB2, CDKN2A, ATM, TP53 and mismatch repair genes MLH1, MSH2, MSH6) have been reported in these patients with the highest prevalence being BRCA1/2. Positive results have been reported with the use of targeted therapies, particularly poly (ADP-ribose) polymerase inhibitors in BRCA-mutated ovarian and breast cancers, and their use is currently being investigated in germline-mutated pancreatic cancer. The aim of this review is to provide an outline of germline DNA damage repair mutations in pancreatic cancer and their effect on the incidence, outcomes and responses to different therapeutic options.
Insights
Pancreatic cancer (PDAC) research reveals germline DNA damage repair mutations, particularly BRCA1/2, influencing disease progression. Understanding these mutations may lead to new targeted therapies for better patient outcomes.
Area of Science:
- Oncology
- Genetics
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has poor prognoses due to limited treatment efficacy.
- Recent decades have seen advancements in understanding DNA damage repair pathways in PDAC.
- Germline mutations in DNA damage repair genes are increasingly recognized in PDAC patients.
Purpose of the Study:
- To review germline DNA damage repair mutations in pancreatic cancer.
- To examine the impact of these mutations on PDAC incidence and patient outcomes.
- To outline the potential of targeted therapies for PDAC with specific mutations.
Main Methods:
- Literature review of studies on germline mutations in pancreatic cancer.
- Analysis of reported mutation frequencies, including BRCA1, BRCA2, PALB2, CDKN2A, ATM, TP53, and mismatch repair genes.
- Examination of treatment responses in relation to specific genetic alterations.
Main Results:
- BRCA1 and BRCA2 mutations show the highest prevalence among germline DNA damage repair mutations in PDAC.
- Targeted therapies, such as poly (ADP-ribose) polymerase inhibitors, show promise.
- These inhibitors have demonstrated efficacy in BRCA-mutated ovarian and breast cancers.
Conclusions:
- Germline DNA damage repair mutations are significant in PDAC.
- Targeted therapies are under investigation for their potential in treating germline-mutated pancreatic cancer.
- Further research into these mutations could improve therapeutic strategies and patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...